Xenograft mouse models still represent the standard for in vivo anti‐leukemic drug efficacy testing in MLL‐rearranged ALL, as to date bona fide genetic mouse models have not yet been reliably established for this type of leukemia. This evidence concerns the gene KMT2A and leukemia.